Published on: June 18, 2015
by James Gallagher for BBC News:
Scientists have discovered a chemical in blood that indicates whether people will have declining brain function.
Looking for the earliest signs of Alzheimer’s disease, they analysed levels of 1,129 proteins circulating in the blood of more than 200 twins.
These were compared with data from cognitive-function tests over the next decade, in Translational Psychiatry.
And levels of one protein, MAPKAPK5, tended to be lower in those people whose brains declined.
MAPKAPK5 is involved in relaying chemical messages within the body, although its connection with cognitive decline is unclear.
Dementia cases are expected to treble globally by 2050, but there is no cure or treatment.
It can take more than a decade from the first changes in the brain to culminate in symptoms such as memory loss, confusion and personality change.
And drug companies believe they need to treat patients years before symptoms appear in order to protect the brain.
Dr Steven Kiddle, a Medical Research Council scientist at King’s College London, told the BBC News website: “People think it may be hard to reverse 20 years of potential damage to your brain.
“But if you could start much earlier in that process, then you might be able to find something that works.”
He said a blood test could help identify people for clinical trials.
But he added: “A test you could go in to your doctor to say, ‘Do I have Alzheimer’s disease or not?’ I think that’s a long way off.”
The twins in the study will have to be followed for many more years to see whether levels of the protein predict dementia.
Dr Eric Karran, from the charity Alzheimer’s Research UK, said: “This study associated blood levels of a protein called MAPKAPK5 with cognitive decline over a 10-year period, but it will be necessary to investigate more about a possible mechanism linking this protein to changes in memory and thinking.
“Current diagnosis of diseases like Alzheimer’s is not an exact science, and we urgently need to improve approaches to deliver more timely and accurate diagnosis.
“Accurate and early diagnosis of Alzheimer’s will be essential for the development of new treatments.”
Older people who report greater levels of social engagement have more robust gray matter in regions of the brain relevant in dementia, according to new research led by scientists at the University of Pittsburgh Graduate School of...
In a new study, University of Nebraska–Lincoln sociologist Marc A. Garcia explored how educational attainment can benefit cognitive health in later life, and whether there are differences in its benefits among minorities. Garcia and his co-authors...
A genetic variation in some people may be associated with cognitive decline that can’t be explained by deposits of two key proteins associated with Alzheimer’s disease, amyloid β and tau, according to a study...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.